Blanca Cantos Sánchez de Ibargüen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Blanca Cantos Sánchez de Ibargüen has a total of 534 co-authors. Here are the top co-authors by number of shared publications:
C. Maximiano
5 shared publicationsA. Ruiz-Valdepeñas
2 shared publicationsD. Pérez Callejo
2 shared publicationsK. Kim
2 shared publicationsM. Méndez García
2 shared publicationsM. Palka
2 shared publications
Latest Publications
- Open Access
- 8 March 2022
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 24 (4) , 703-711
SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021)
Central nervous system (CNS) dissemination is a severe complication in cancer and a leading cause of cancer-related mortality. Brain metastases (BMs) are the most common types of malignant intracranial tumors and are reported in approximately 25% of patients with metastatic cancers. The recent increase in incidence of BMs is due to several factors including better diagnostic assessments and the development of improved systemic therapies that have lower activity on the CNS. However, newer systemic therapies are being developed that can cross the blood–brain barrier giving us additional tools to treat BMs. The guidelines presented here focus on the efficacy of new targeted systemic therapies and immunotherapies on CNS BMs from breast, melanoma, and lung cancers.
- 8 March 2022
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 24 (4) , 703-711
Open AccessSEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021)
Central nervous system (CNS) dissemination is a severe complication in cancer and a leading cause of cancer-related mortality. Brain metastases (BMs) are the most common types of malignant intracranial tumors and are reported in approximately 25% of patients with metastatic cancers. The recent increase in incidence of BMs is due to several factors including better diagnostic assessments and the development of improved systemic therapies that have lower activity on the CNS. However, newer systemic therapies are being developed that can cross the blood–brain barrier giving us additional tools to treat BMs. The guidelines presented here focus on the efficacy of new targeted systemic therapies and immunotherapies on CNS BMs from breast, melanoma, and lung cancers.
- Open Access
- 1 September 2012
- Published by Elsevier in Annals of Oncology
- Vol. 23, ix492-ix498
Phase II Study of Amrubicin in Patients with Refractory or Resistant Relapsed Small-Cell Lung Cancer: Japan Clinical Oncology Group Study (JCOG0901)
Standard therapy for refractory or resistant relapsed small-cell lung cancer (SCLC) has not yet been established. We conducted an open-label, multicenter, non-randomized phase II study to confirm the efficacy and safety of amrubicin, a topoisomerase inhibitor, in the treatment of refractory or resistant SCLC.
- 1 September 2012
- Published by Elsevier in Annals of Oncology
- Vol. 23, ix492-ix498
Open AccessPhase II Study of Amrubicin in Patients with Refractory or Resistant Relapsed Small-Cell Lung Cancer: Japan Clinical Oncology Group Study (JCOG0901)
Standard therapy for refractory or resistant relapsed small-cell lung cancer (SCLC) has not yet been established. We conducted an open-label, multicenter, non-randomized phase II study to confirm the efficacy and safety of amrubicin, a topoisomerase inhibitor, in the treatment of refractory or resistant SCLC.
- Open Access
- 1 September 2012
- Published by Elsevier in Annals of Oncology
- Vol. 23 (suppl_9) , ix447-ix461
Risk of Major Bleeding in Cancer Patients Receiving Chemotherapy
Cancer patients receiving chemotherapy are at increased risk of venous thromboembolism (VTE). The presence of cancer and anticoagulant use are risk factors for bleeding, yet data on bleeding risk are limited in these patients. This analysis evaluated the risk of major bleeding in cancer patients receiving chemotherapy using a US claims database. This retrospective cohort study used the MarketScan® databases, a nationwide database containing data from about 100 payers and covering > 30 million patients annually. Adult cancer patients receiving chemotherapy within 6 months of cancer diagnosis between January 2004 and December 2010 were included. Cancers of interest were: lung, colon/rectum, pancreas, bladder, stomach, and ovary. The index date was the first date of chemotherapy. Patients were followed until the earliest of: 1) first diagnosis of major bleeding; 2) termination of enrolment in the health plan; 3) end of study. The primary outcome was the first occurrence of major bleeding, based on selected ICD-9-CM/CPT codes, following chemotherapy initiation. Of 74,575 patients identified, exclusion of those with prior history of bleeding at baseline (∼5%) resulted in 70,822 patients included in the analysis. Mean age was 62 years, 37% were ≥ 65 years, and 52% were male. Average time of follow up and chemotherapy were 14.3 and 8.6 months, respectively; 6% had a history of VTE within 6 months prior to the index date. Major bleeding occurred in 5.8% of patients and the incidence rate for all cancers combined was 4.9 per 100 person-year (PY) and 10.5, 9.3, 6.2, 4.3, 3.6, and 3.3/100 PY for pancreatic, stomach, lung, bladder, colon/rectum, and ovarian cancer, respectively. Approximately 14% of patients (N = 10,456) developed VTE after chemotherapy initiation (> half in the first 3 months of chemotherapy treatment). Of these, 7.8% experienced major bleeding with incidence rates ranging from 5.9-17.7/100 PY after VTE. Major bleeding incidence in cancer patients receiving chemotherapy varies by cancer type with the highest rates in patients with upper gastrointestinal cancer. Compared to the overall cohort, major bleeding risk was higher in cancer patients who developed VTE.
- 1 September 2012
- Published by Elsevier in Annals of Oncology
- Vol. 23 (suppl_9) , ix447-ix461
Open AccessRisk of Major Bleeding in Cancer Patients Receiving Chemotherapy
Cancer patients receiving chemotherapy are at increased risk of venous thromboembolism (VTE). The presence of cancer and anticoagulant use are risk factors for bleeding, yet data on bleeding risk are limited in these patients. This analysis evaluated the risk of major bleeding in cancer patients receiving chemotherapy using a US claims database. This retrospective cohort study used the MarketScan® databases, a nationwide database containing data from about 100 payers and covering > 30 million patients annually. Adult cancer patients receiving chemotherapy within 6 months of cancer diagnosis between January 2004 and December 2010 were included. Cancers of interest were: lung, colon/rectum, pancreas, bladder, stomach, and ovary. The index date was the first date of chemotherapy. Patients were followed until the earliest of: 1) first diagnosis of major bleeding; 2) termination of enrolment in the health plan; 3) end of study. The primary outcome was the first occurrence of major bleeding, based on selected ICD-9-CM/CPT codes, following chemotherapy initiation. Of 74,575 patients identified, exclusion of those with prior history of bleeding at baseline (∼5%) resulted in 70,822 patients included in the analysis. Mean age was 62 years, 37% were ≥ 65 years, and 52% were male. Average time of follow up and chemotherapy were 14.3 and 8.6 months, respectively; 6% had a history of VTE within 6 months prior to the index date. Major bleeding occurred in 5.8% of patients and the incidence rate for all cancers combined was 4.9 per 100 person-year (PY) and 10.5, 9.3, 6.2, 4.3, 3.6, and 3.3/100 PY for pancreatic, stomach, lung, bladder, colon/rectum, and ovarian cancer, respectively. Approximately 14% of patients (N = 10,456) developed VTE after chemotherapy initiation (> half in the first 3 months of chemotherapy treatment). Of these, 7.8% experienced major bleeding with incidence rates ranging from 5.9-17.7/100 PY after VTE. Major bleeding incidence in cancer patients receiving chemotherapy varies by cancer type with the highest rates in patients with upper gastrointestinal cancer. Compared to the overall cohort, major bleeding risk was higher in cancer patients who developed VTE.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , e18537
Late relapses in Hodgkin's disease.
E18537 Background: Survival in Hodgkin's Disease (HD) has significantly increased. There is no consensus on the definition of late relapse in Hodgkin's Disease. No consistent prognostic factors for the development of late relapse have been identified. There are very few studies on this situation.We analyze late relapses, beyond five years, on how they are diagnosed, their behavior and the characteristics associated with them. Methods: We reviewed the database of patients with HD in our hospital (1967-2005). To obtain our study population, we have reviewed the database of patients with Hodgkin's Disease treated in our hospital between the years 1967 and 2005 and selected those who had relapses of their disease after achieving complete remission with the first line of treatment. Patients were prospectively followed up from their diagnosis every 3 months during the first 2 years, every 6 months between 2 and 5 years, and annually from the fifth year on. Results: We studied 534 with HD. Disease-free survival in this series was 83% at two years and 68% at 5 years, although without reaching the median follow-up. We found 150 relapses (27%), 30 of which occurred five years after the end of treatment. The relapses were detected in a scheduled appointment in 16 (54%) asymptomatic patients. 7/30 patients had a different histological type. There were no statistically significant differences in survival between those patients with a late relapse and new remission and those who never relapsed. Conclusions: Long-term survival was not significantly different in relapsed patients with remission after treatment from that of patients never relapsed. Late relapses in Hodgkin's Disease needs to be analyzed separately, perhaps linked to the biological behavior of the tumor. We need to individualize treatment according to location of relapse and maintain active follow-ups to detect late and recoverable relapses No significant financial relationships to disclose.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , e18537
Late relapses in Hodgkin's disease.
E18537 Background: Survival in Hodgkin's Disease (HD) has significantly increased. There is no consensus on the definition of late relapse in Hodgkin's Disease. No consistent prognostic factors for the development of late relapse have been identified. There are very few studies on this situation.We analyze late relapses, beyond five years, on how they are diagnosed, their behavior and the characteristics associated with them. Methods: We reviewed the database of patients with HD in our hospital (1967-2005). To obtain our study population, we have reviewed the database of patients with Hodgkin's Disease treated in our hospital between the years 1967 and 2005 and selected those who had relapses of their disease after achieving complete remission with the first line of treatment. Patients were prospectively followed up from their diagnosis every 3 months during the first 2 years, every 6 months between 2 and 5 years, and annually from the fifth year on. Results: We studied 534 with HD. Disease-free survival in this series was 83% at two years and 68% at 5 years, although without reaching the median follow-up. We found 150 relapses (27%), 30 of which occurred five years after the end of treatment. The relapses were detected in a scheduled appointment in 16 (54%) asymptomatic patients. 7/30 patients had a different histological type. There were no statistically significant differences in survival between those patients with a late relapse and new remission and those who never relapsed. Conclusions: Long-term survival was not significantly different in relapsed patients with remission after treatment from that of patients never relapsed. Late relapses in Hodgkin's Disease needs to be analyzed separately, perhaps linked to the biological behavior of the tumor. We need to individualize treatment according to location of relapse and maintain active follow-ups to detect late and recoverable relapses No significant financial relationships to disclose.
- Open Access
- 1 January 2007
- Published by SciELO Espana/Repisalud in Oncología (Barcelona)
- Vol. 30 (3) , 50-52
Hemoperitoneo en GIST metastásico
- 1 January 2007
- Published by SciELO Espana/Repisalud in Oncología (Barcelona)
- Vol. 30 (3) , 50-52
Open AccessHemoperitoneo en GIST metastásico